Acadia Pharmaceuticals | ACAD - Koszty Sprzedaży I Administracji





Koszty Sprzedaży I Administracji Zmiana Data
Acadia Pharmaceuticals USD 148.57M 12.22M 2026-06
ALKERMES USD 196.64M 67.96M 2026-06
Alnylam Pharmaceuticals USD 347.92M 65.41M 2026-06
Biogen USD 709.7M 155.4M 2026-06
BioMarin Pharmaceutical USD 395.55M 137.27M 2026-06
Bristol-Myers Squibb USD 1.83B 209M 2026-06
Cara Therapeutics USD 2.09M 96K 2026-03
Corcept Therapeutics USD 156.9M 28.85M 2026-06
Cytokinetics USD 104.4M 499K 2026-06
Eisai JPY 114.83B 4.71B 2026-06
Eli Lilly USD 3.43B 496M 2026-06
Incyte USD 351.73M 23.64M 2026-06
J&J USD 6.42B 381M 2026-06
Moderna USD 216M 43M 2026-06
Neurocrine Biosciences USD 383.1M 64.6M 2026-06
Pfizer USD 3.41B 496M 2026-06
Prothena USD 12.67M 5.02M 2026-03
PTC Therapeutics USD 73.89M 13.31M 2026-03
Sarepta Therapeutics USD 107.6M 53.57M 2026-06
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
Vanda Pharmaceuticals USD 39.28M 1.71M 2024-12
Vertex Pharmaceuticals USD 582.2M 88.5M 2026-06